Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152612 | 1.00 | LPAR3 (0.49) | LPAR3LPAR2LPAR1GPR84P2RY10 | |
| SCHEMBL7153050 | 1.00 | LPAR3 (0.49) | LPAR3LPAR2LPAR1GPR84P2RY10 | |
| SCHEMBL4095718 | 0.86 | LPAR3 (0.51) | LPAR3LPAR2LPAR1GPR84P2RY10 | |
| SCHEMBL2364791 | 0.85 | LPAR3 (0.48) | LPAR3LPAR2LPAR1P2RY10LPAR5 | |
| SCHEMBL14561060 | 0.79 | POLB (0.41) | — | |
| SCHEMBL11688744 | 0.79 | CYP3A4 (0.42) | LPAR3LPAR2LPAR1GPR84P2RY10 | |
| SCHEMBL14740722 | 0.78 | PLA2G2C (0.46) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL14445604 | 0.76 | CYP3A4 (0.47) | LPAR3LPAR2LPAR1GPR84MMP9 | |
| SCHEMBL7797031 | 0.75 | LPAR3 (0.46) | LPAR3LPAR2LPAR1 | |
| Phosphoric Acid Monotetradecyl Ester SCHEMBL29057382 | 0.75 | LPAR3 (0.64) | LPAR3LPAR2LPAR1GPR84LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226544-A1 | ION-SELECTIVE MEMBRANE, ION-SELECTIVE ELECTRODE, ION SENSOR, SPECIMEN TESTING DEVICE, AND COMPLEX COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2023-07-20 | — | — | US | disclosed |
| US-6635683-B1 | Membrane containing onium salt and aromatic boric diester compounds; rapid measurement in body fluids; high sensitivity and selectivity; long life | TOKUYAMA CORPORATION (JP) | 2003-10-21 | — | — | US | disclosed |
| EP-1096251-A1 | FILM RESPONSIVE TO BICARBONATE ION | TOKUYAMA CORPORATION (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226544-A1 | ION-SELECTIVE MEMBRANE, ION-SELECTIVE ELECTRODE, ION SENSOR, SPECIMEN TESTING DEVICE, AND COMPLEX COMPOUND | LETM1, TIMM9, TMEM109 | LPAR3 4121/4885LPAR2 3427/4885LPAR1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.